2006
E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer
Lin J, Dinney C, Grossman H, Jhamb M, Zhu Y, Spitz, Wu X. E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer. Clinical Genetics 2006, 70: 240-245. PMID: 16922727, DOI: 10.1111/j.1399-0004.2006.00666.x.Peer-Reviewed Original ResearchConceptsSuperficial bladder cancerBladder cancer recurrenceBladder cancerCancer recurrencePromoter polymorphismHazard ratioCaucasian patientsMedian recurrence-free survivalMedical chart reviewRecurrence-free survivalRisk of recurrencePeripheral blood lymphocytesProportional hazards modelHomozygous CC genotypeChart reviewDisease recurrenceSmoking statusTumor recurrenceTumor stageBlood lymphocytesClinical dataCC genotypeHazards modelPatientsRecurrence risk
2005
Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer
Gu J, Zhao H, Dinney C, Zhu Y, Leibovici D, Bermejo C, Grossman H, Wu X. Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer. Clinical Cancer Research 2005, 11: 1408-1415. PMID: 15746040, DOI: 10.1158/1078-0432.ccr-04-1101.Peer-Reviewed Original ResearchMeSH KeywordsAgedAllelesBCG VaccineDisease ProgressionDNA HelicasesDNA RepairDNA Repair EnzymesDNA-Binding ProteinsFemaleFollow-Up StudiesGene FrequencyGenotypeHumansMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalPoly-ADP-Ribose Binding ProteinsPolymorphism, GeneticSurvival AnalysisTime FactorsUrinary Bladder NeoplasmsXeroderma Pigmentosum Group A ProteinConceptsBacillus Calmette-Guerin treatmentRecurrence-free survival timeSuperficial bladder cancerShorter recurrence-free survival timeHigh recurrence riskDNA repair capacityHigh-risk allelesRecurrence riskPutative high-risk alleleVariant allelesClinical outcomesBladder cancerSurvival timeIntravesical bacillus Calmette-Guerin treatmentGene polymorphismsSuperficial bladder cancer recurrenceRepair capacityNucleotide excision repair gene polymorphismsRisk allelesCancer treatmentBladder cancer outcomesBladder cancer recurrenceBladder cancer treatmentMore risk allelesEnd of observation